Medtronic’s Market Position: Balancing Growth Opportunities and Challenges

BTIG analyst Ryan Zimmerman has maintained their neutral stance on MDT stock, giving a Hold rating on June 30.

Ryan Zimmerman has given his Hold rating due to a combination of factors influencing Medtronic’s current market position. The recent proposal by CMS to cover Renal Denervation for uncontrolled hypertension is seen as a positive development for Medtronic, potentially opening up a large patient pool. However, the implementation of this coverage is expected to be gradual, as it requires facilities to meet specific criteria, which could slow initial adoption.
Additionally, while Medtronic is expected to achieve consistent top-line growth, macroeconomic challenges such as tariffs and increased operating expenses from new product launches may constrain earnings growth in the near term. Despite these challenges, Medtronic’s efforts to optimize its portfolio are viewed positively, with a more favorable outlook anticipated for FY27. These mixed factors contribute to Zimmerman’s decision to maintain a Neutral stance on the stock.